Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha ® (evolocumab) ...
(Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to ...
All 23 claims of the ‘631 patent exclusively licensed to TwinStrand remain intact following unappealable decision on ...
The recently appointed CEO, a former Moderna scientist and Brown University Ph.D., will grow the Brown spinout from its first ...
Tsingke Biotech ("Tsingke"), a provider of nucleic acid and gene synthesis solutions, is advancing its "AI + Molecular ...
EIT Pharma, Inc. ("EIT Pharma" or the "Company"), a biotechnology company focused on developing therapies for infectious ...
Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of ...
ROBBIN Phase 3 on track for first patient enrolled in Q1 2027; strong global investigator engagement advances preparations ...
UK trial sites join the pivotal study of first-in-class anti-biofilm drug candidate designed to cure medical device-related ...
New Agentic AI tools for protein discovery and disease trend prediction take iSpecimen beyond its biospecimen marketplace ...
November 5, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (now Mentari Therapeutics, Inc.) (the "Company"), a ...
AstraZeneca has apparently made a $10 billion bid to acquire Rhythm Pharmaceuticals, an offer William Blair suspects will not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results